A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

Prior treatment

• Previous surgical or/and transcatheter cardiac valve replacement at any site
• Previous open-heart surgical valve repair at any site
• Any percutaneous cardiovascular intervention (excluding diagnostic percutaneous coronary artery intervention), cardiovascular surgery, carotid surgery within 30 days
• Acute myocardial infarct within the previous 30 days
• Previous organ transplant or currently an organ transplant candidate Anatomical
• Known intolerance for periprocedural/post-procedural anticoagulation or antiplatelet therapy leading to be unable to undergo index procedure per physicians' judgement
• Planned relevant concomitant procedure within 30 days post index procedure
• Current or recent participation (within 6 weeks prior to index procedure) in another drug or device trial

Other illness

• Untreated mitral, tricuspid, or pulmonary valve diseases requiring procedural intervention
• Untreated clinically significant coronary artery diseases requiring revascularization
• Severe right heart dysfunction
• Active infection requiring antibiotic therapy including infective endocarditis
• Stroke or TIA within 3 months or Modified Rankin Scale ≥ 4 disability
• Severe chronic lung disease
• Hemodynamics instability requiring inotropic support or intra-aortic balloon pump (IABP) or other hemodynamic support device, or any mechanical heart assistance
• Life expectancy ≤ 1 year due to non-cardiac reasons

Lab values

• Chronic kidney disease (eGFR\<45 mL/min/1.73m2) or end-stage renal disease requiring chronic dialysis
• Hematologic disorders: Leukopenia (WBC \< 3000 cell/mL), anemia (Hgb \< 9 g/dL), thrombocytopenia (Plt\< 50,000 cell/mL), or any known blood clotting disorder, deemed clinically significant after consultation with Hematooncology specialists
• LVEF \< 20%

Other

• Hypertrophic obstructive cardiomyopathy (HOCM)
• Severe symptomatic carotid artery stenosis
• Left ventricular end diastolic diameter (LVEDD) \>70mm
• Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
• Native aortic valve geometry and size unfavorable for study bioprosthetic valve General
• Urgent, emergency or salvage surgeries
• Pregnant, breastfeeding or intend to become pregnant within 1 year
• Currently incarcerated or unable to give voluntary informed consent

• Age ≥ 18 years
• Patients who are clinically indicated for aortic valve replacement
• Patients who are willing and able to participate in the follow-up requirements, and provide written informed consent